IP Library Granted Patent US 7,410,798
Granted Patent B2
US 7,410,798 · App. 10/235,094 · Granted Aug 12, 2008

Culture system for rapid expansion of human embryonic stem cells

Assignee: Geron Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,410,798
App. No.
10/235,094
Granted
Aug 12, 2008
Kind
B2
Abstract

This disclosure provides an improved system for culturing human pluripotent stem cells. Traditionally, pluripotent stem cells are cultured on a layer of feeder cells (such as mouse embryonic fibroblasts) to prevent them from differentiating. In the system described here, the role of feeder cells is replaced by components added to the culture environment that support rapid proliferation without differentiation. Effective features are a suitable support structure for the cells, and an effective medium that can be added fresh to the culture without being preconditioned by another cell type. Culturing human embryonic stem cells in fresh medium according to this invention causes the cells to expand surprisingly rapidly, while retaining the ability to differentiate into cells representing all three embryonic germ layers. This new culture system allows for bulk proliferation of pPS cells for commercial production of important products for use in drug screening and human therapy.

Claims (13)

1. A method for culturing a population of human embryonic stem (hES) cells in an undifferentiated state, comprising culturing the hES cell population in a culture environment containing the following components:

i) an extracellular matrix;

ii) a non-conditioned culture medium; and

iii) 40 ng/ml of a fibroblast growth factor;

wherein the culture environment is essentially free of feeder cells.

2. The method of claim 1 , wherein the fibroblast growth factor is basic fibroblast growth factor.

3. The method of claim 1 , wherein the fibroblast growth factor is fibroblast growth factor-4 (FGF-4).

4. The method of claim 1 , wherein the extracellular matrix is selected from Matrigel, laminin, fibronectin, and entactin.

5. The method of claim 4 , wherein the extracellular matrix is laminin.

6. The method of claim 4 , wherein the extracellular matrix is Matrigel.

7. The method of claim 4 , wherein the extracellular matrix is fibronectin.

8. The method of claim 1 , wherein the culture environment further comprises stem cell factor (SCF).

9. The method of claim 1 , wherein the culture environment further comprises Flt3 ligand.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2013
From: GERON CORPORATION
To: ASTERIAS BIOTHERAPEUITCS, INC.
Reel/Frame 031578/0054 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2002
From: MANDALAM, RAMKUMAR; XU, CHUNHUI; GOLD, JOSEPH D.; CARPENTER, MELISSA K.
To: GERON CORPORATION
Reel/Frame 013275/0210 →
Continuity (3)
Provisional Application 6031747800 · Sep 5, 2001
Related Publication 20030017589A1 · Jan 23, 2003
Related Publication 20080020458A9 · Jan 24, 2008